Eupraxia Pharmaceuticals Inc. (EPRX) Balance Sheet
EPRX balance sheet, 2025
December 31, 2025 · U.S. dollars$86.2M assets = $5.7M liabilities + $80.4M equity
Both columns are drawn to the same scale: what EPRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
EPRX financial health
Descriptive bands, not a rating. Fiscal 2025.
EPRX balance sheet trends, 2017–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $5.9M2017 | $86.2M2025 | +144.0%/yr | |
| Total liabilities | $735,8152017 | $5.7M2025 | +97.9%/yr | |
| Shareholders’ equity | $6.0M2017 | $82.0M2025 | +139.4%/yr | |
| Cash & short-term investments | $4.0M2017 | $80.6M2025 | +171.0%/yr | |
| Total debt | $12,4742017 | $154,3622025 | +131.3%/yr | |
| Net cash (debt) | $4.0M2017 | $80.4M2025 | +$76.4M | |
| Working capital | $4.8M2017 | $79.5M2025 | +$74.7M | |
| Book value per share | $0.982024 | $2.052025 | +108.6%/yr | |
| Debt / equity | 0.002017 | 0.002025 | 0.00 | |
| Shares outstanding | 33.9M2024 | 40.0M2025 | +17.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
EPRX assets
EPRX liabilities and equity
EPRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
EPRX balance sheet
| 2025 | 2024 | 2018 | 2017 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $80.6M | $33.1M | $823,481 | $4.0M |
| Cash & equivalents | $80.6M | $33.1M | $823,481 | $4.0M |
| Receivables | $674,226 | $228,872 | $1.5M | $1.3M |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $3.9M | $1.1M | $171,451 | $122,588 |
| Total current assets | $85.1M | $34.4M | $2.5M | $5.5M |
| Property, plant & equipment (net) | $987,126 | $424,916 | $435,468 | $419,438 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $64,332 | $80,761 | $0 | $6,132 |
| Total assets | $86.2M | $34.9M | $2.9M | $5.9M |
| Liabilities | ||||
| Short-term debt | $78,452 | $71,859 | $3.8M | $7,342 |
| Total current liabilities | $5.6M | $3.1M | $14.3M | $730,683 |
| Long-term debt | $0 | $0 | $0 | $0 |
| Lease obligations | $154,362 | $71,859 | — | — |
| Other long-term liabilities | $75,910 | $0 | $0 | $5,132 |
| Total liabilities | $5.7M | $3.1M | $14.3M | $735,815 |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $195.4M | $116.4M | $23.5M | $23.6M |
| Retained earnings (deficit) | −$169.6M | −$131.0M | −$40.0M | −$20.1M |
| Accumulated other comprehensive income | −$2.0M | −$4.2M | — | — |
| Minority interest | −$1.6M | −$1.6M | — | — |
| Total shareholders' equity | $82.0M | $33.4M | −$11.1M | $6.0M |
| Key figures | ||||
| Total debt | $154,362 | $71,859 | $3.8M | $12,474 |
| Net cash (debt) | $80.4M | $33.0M | −$3.0M | $4.0M |
| Working capital | $79.5M | $31.3M | −$11.9M | $4.8M |
| Tangible book value | $82.0M | $33.4M | −$11.1M | $6.0M |
| Book value per share | $2.05 | $0.98 | — | — |
| Shares outstanding | 40.0M | 33.9M | — | — |
| Current ratio | 15.12 | 11.10 | 0.17 | 7.53 |
| Quick ratio | 14.43 | 10.74 | 0.16 | 7.36 |
| Debt / equity | 0.00 | 0.00 | — | 0.00 |
| Equity / assets | 95.2% | 95.6% | −380.1% | 100.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $133.4M | $138.9M | $80.6M | $89.0M | $19.8M | $27.5M | $33.1M | $8.7M | $23.3M |
| Cash & equivalents | $52.3M | $58.5M | $80.6M | $89.0M | $19.8M | $27.5M | $33.1M | $8.7M | $23.3M |
| Short-term investments | $81.1M | $80.4M | — | — | — | — | — | — | $8.6M |
| Receivables | $0 | $663,235 | $674,226 | $139,904 | $134,607 | $238,531 | $228,872 | $105,930 | $155,235 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $841,456 |
| Other current assets | $3.1M | $2.6M | $3.9M | $2.3M | $2.9M | $913,283 | $1.1M | $1.1M | $212,394 |
| Total current assets | $136.5M | $142.1M | $85.1M | $91.4M | $22.8M | $28.6M | $34.4M | $9.9M | $24.5M |
| Property, plant & equipment (net) | $3.0M | $3.2M | $987,126 | $851,595 | $688,325 | $546,537 | $424,916 | $456,493 | $445,526 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $53,108 | $61,754 | $64,332 | $97,597 | $77,842 | $80,230 | $80,761 | $18,430 | $4,602 |
| Total assets | $139.6M | $145.4M | $86.2M | $92.3M | $23.6M | $29.2M | $34.9M | $10.4M | $25.0M |
| Liabilities | |||||||||
| Accounts payable | $8.4M | $7.2M | — | $3.7M | — | — | — | — | — |
| Short-term debt | $159,566 | $203,510 | $78,452 | $76,136 | $35,065 | $52,774 | $71,859 | $78,752 | $4.6M |
| Total current liabilities | $8.5M | $7.4M | $5.6M | $3.8M | $2.6M | $2.2M | $3.1M | $2.4M | $11.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $1.8M | $2.0M | $154,362 | $170,603 | $35,065 | $52,774 | $71,859 | $93,049 | $105,960 |
| Other long-term liabilities | $1.7M | $1.8M | $75,910 | $94,467 | $0 | $0 | $0 | $14,297 | $34,952 |
| Total liabilities | $10.2M | $9.2M | $5.7M | $3.9M | $2.6M | $2.2M | $3.1M | $2.4M | $11.6M |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $263.7M | $255.5M | $195.4M | $191.0M | $117.1M | $116.8M | $116.4M | $116.3M | $116.3M |
| Retained earnings (deficit) | −$196.3M | −$182.2M | −$169.6M | −$152.9M | −$146.5M | −$137.8M | −$131.0M | −$123.5M | −$117.6M |
| Accumulated other comprehensive income | −$7.0M | −$4.5M | −$2.0M | −$3.3M | −$2.8M | −$4.1M | −$4.2M | −$2.8M | −$2.9M |
| Minority interest | −$1.6M | −$1.6M | −$1.6M | −$1.6M | −$1.6M | — | — | — | — |
| Total shareholders' equity | $131.0M | $137.8M | $82.0M | $90.0M | $22.6M | $28.6M | $33.4M | $9.5M | $14.8M |
| Key figures | |||||||||
| Total debt | $1.8M | $2.0M | $154,362 | $170,603 | $35,065 | $52,774 | $71,859 | $93,049 | $4.7M |
| Net cash (debt) | $131.6M | $136.9M | $80.4M | $88.8M | $19.7M | $27.4M | $33.0M | $8.6M | $18.7M |
| Working capital | $128.0M | $134.8M | $79.5M | $87.6M | $20.2M | $26.4M | $31.3M | $7.5M | $12.9M |
| Tangible book value | $131.0M | $137.8M | $82.0M | $90.0M | $22.6M | $28.6M | $33.4M | $9.5M | $14.8M |
| Book value per share | $1.98 | $2.43 | $1.58 | $2.44 | $0.63 | $0.80 | $0.94 | $0.27 | $0.42 |
| Shares outstanding | 66.2M | 56.7M | 51.9M | 36.9M | 35.9M | 35.7M | 35.6M | 35.6M | 35.6M |
| Current ratio | 16.00 | 19.30 | 15.12 | 23.98 | 8.72 | 13.00 | 11.10 | 4.17 | 2.11 |
| Quick ratio | 15.63 | 18.95 | 14.43 | 23.38 | 7.60 | 12.59 | 10.74 | 3.70 | 2.02 |
| Debt / equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.31 |
| Equity / assets | 93.8% | 94.8% | 95.2% | 97.5% | 95.6% | 97.8% | 95.6% | 91.9% | 59.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 13, 2026); data from EODHD.
EPRX financial position
At the end of fiscal 2025 (December 31, 2025), Eupraxia Pharmaceuticals had total assets of $86.2 million (up 146.5% from a year earlier), total liabilities of $5.7 million and shareholders' equity of $82.0 million. It held $80.6 million in cash and short-term investments against $0.2 million of debt, a net cash position of $80.4 million. Its current ratio was 15.12. In the latest quarter (ended June 30, 2026) total assets were $139.6 million and equity $131.0 million.
Related: EPRX income statement, EPRX cash flow statement, EPRX key metrics. See the EPRX stock overview for the latest quote and news.
EPRX balance sheet FAQ
What are Eupraxia Pharmaceuticals's total assets?
Eupraxia Pharmaceuticals reported total assets of $86.2 million at the end of fiscal 2025 (December 31, 2025), compared with $34.9 million a year earlier.
How much debt does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals had $0.2 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.
How much cash does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals held $80.6 million in cash and short-term investments at the end of fiscal 2025; with $0.2 million of debt that is net cash of $80.4 million.
What is Eupraxia Pharmaceuticals's book value?
Eupraxia Pharmaceuticals's shareholders' equity (book value) was $82.0 million at the end of fiscal 2025, or $2.05 per share.
What is Eupraxia Pharmaceuticals's current ratio?
Eupraxia Pharmaceuticals had current assets of $85.1 million and current liabilities of $5.6 million, a current ratio of 15.12 (it can cover its short-term obligations).